Sentences with phrase «gene editing company»

Not exact matches

Shares of pioneering CRISPR gene - editing firm Editas fell 7 % in early Tuesday trading after the company announced that it would delay an initial FDA filing for clinical trials of one of its lead drugs, LCA10, to the middle of next year (Editas had originally planned to file by the end of 2017).

• Calyxt, the New Brighton, Minn. - based company based on gene - editing foods, filed for a $ 50 million IPO Friday.

There are a handful of public companies in the industry, including gene editing Intellia Therapeutics, which raised $ 108 million in its 2016 IPO.

Now that the barrier of editing genes in the hospital setting has been broken, these companies and more have pipelines of gene - editing innovation coming to a hospital near you in the next few years, as clinical trials are approved and new ways to cure formerly incurable diseases go mainstream in our lifetimes.

• Excision BioTherapeutics, a Philadelphia - based life science company focused on the development and commercialization of advanced gene editing therapeutics for the treatment of life - threatening disease caused by neurotropic viruses, raised $ 10 million in seed funding.

• Calyxt, the New Brighton, Minn. - based company based on gene - editing foods, said it would offer 7 million shares at $ 8 — at the low end of its range of $ 8 to $ 10.

Without doubting the importance of what they call «the gene - editing explosion,» they aren't yet sure of the value of Crispr - Cas9 to their company.

Ultimately, enhancements of many kinds will «definitely» happen in the future, says Fyodor Urnov of Sangamo BioSciences, a company that is working in the gene editing space.

Many groups, including Urnov's company, are already using gene - editing tools to develop therapies that correct genetic defects in people (such as by editing white blood cells).

The company aims to use CRISPR gene - editing to craft RNA therapeutics that can be delivered into the central nervous system — clearly a daunting task for most drug makers.

The track record of earlier gene - editing approaches suggests that the CRISPR companies pursuing medical therapies have a long road ahead.

The first author is Edward Lanphier, the «president and CEO of Sangamo BioSciences in Richmond, California, a company that hopes to use gene - editing technology to treat patients.»

They hope that such a discussion would help the public understand the difference between genome editing in a person's somatic cells — cells other than sperm and egg cells — and editing in cells that could pass the changes on to future generations, says Lanphier, who is president and CEO of Sangamo BioSciences in Richmond, California, a company that hopes to use gene - editing technology to treat patients.

«I am thrilled to join Caribou at such an exciting time for the Company and the field of CRISPR gene editing,» said Dr. Kanner.

Several biotechnology companies are using the gene editing technique in an effort to develop therapies for treating genetic diseases, including CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine.

«With extensive experience at both large and small agriculture and industrial biotech companies, she is uniquely positioned to help Caribou capitalize on the potential opportunities for CRISPR - Cas gene editing to develop improved crops and bio-based products.»

CRISPR Therapeutics is pioneering a new class of medicines, to conduct the first company - sponsored clinical trial of a CRISPR gene - edited therapy.

PULLMAN, Wash. — A gene editing technology developed at Washington State University is being licensed to Genus plc, a global animal genetics company, to develop cattle that are more resistant to bovine respiratory disease (BRD).